Citi says MoonLake Immunotherapeutics (MLTX) takeover thesis has reemerged after the Financial Times reported Merck (MRK) expressed interested in acquiring MoonLake and submitted a non-binding offer for more than $3B earlier this year. The offer was reportedly rejected, which is unsurprising given the $3B price would represent only a 16% premium over Monday’s close, the analyst tells investors in a research note. The firm says its $72 per share price target implies a $4.5B valuation. It continues to believe MoonLake’s sonelokimab has the potential to demonstrate differentiated efficacy versus competitor Bimzelx. Citi keeps a Buy rating on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- Closing Bell Movers: Credo Technology jumps 11% on earnings
- Merck held talks to buy MoonLake for over $3B, FT reports
- MoonLake Immunotherapeutics: Promising Clinical Developments and Strong Financial Position Justify Buy Rating
- Wolfe upgrades MoonLake Immunotherapeutics ahead of sonelokimab data
- MoonLake upgraded to Outperform from Peer Perform at Wolfe Research
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue